Pevonedistat
- Generic Name
- Pevonedistat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N5O4S
- CAS Number
- 905579-51-3
- Unique Ingredient Identifier
- S3AZD8D215
- Background
Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT03813147
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 17
- Registration Number
- NCT03814005
- Locations
- 🇪🇸
ICO lHospitalet Hospital Duran i Reynals, LHospitalet de Llobregat, Barcelona, Spain
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT03772925
- Locations
- 🇺🇸
Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
- Conditions
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 8
- Registration Number
- NCT03770260
- Locations
- 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03745352
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03709576
- Locations
- 🇺🇸
Penn State Hershey Medical Center: Penn State Cancer Institute, Hershey, Pennsylvania, United States
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03486314
- Locations
- 🇺🇸
Greenville Health System - Institute for Translational Oncology Research, Greenville, South Carolina, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
- Conditions
- B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT03479268
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Justin Watts, MD
- Target Recruit Count
- 12
- Registration Number
- NCT03459859
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT03386214
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.